Areas of Research
- Breast Cancer
- Cell Signaling
- Pancreatic Cancer
- Tumor Microenvironment
- Cancer Metastasis
- Cancer Biology
- Targeted Therapy
Welcome to the Yu Lab at MD Anderson Cancer Center! We perform translational research on several types of cancers, such as breast and pancreatic, specializing in brain metastasis. Our laboratory functions as a bridge connecting basic and translational cancer research to important issues in cancer patient care.
- Yuan X, Duan Y, Xiao Y, Sun K, Qi Y, Zhang Y, Ahmed Z, Moiani D, Yao J, Li H, Zhang L, Yuzhalin AE, Li P, Zhang C, Badu-Nkansah A, Saito Y, Liu X, Kuo WL, Ying H, Sun SC, Chang JC, Tainer JA, Yu D. Vitamin E Enhances Cancer Immunotherapy by Reinvigorating Dendritic Cells via Targeting Checkpoint SHP1. Cancer Discov 12(7):1742-1759, 2022. e-Pub 2022. PMID: 35420681.
- Zhang L, Qu J, Qi Y, Duan Y, Huang YW, Zhou Z, Li P, Yao J, Huang B, Zhang S, Yu D. EZH2 engages TGFβ signaling to promote breast cancer bone metastasis via integrin β1-FAK activation. Nat Commun 13(1):2543, 2022. e-Pub 2022. PMID: 35538070.
- Li H, Xiao Y, Li Q, Yao J, Yuan X, Zhang Y, Yin X, Saito Y, Fan H, Li P, Kuo WL, Halpin A, Gibbons DL, Yagita H, Zhao Z, Pang D, Ren G, Yee C, Lee JJ, Yu D. The allergy mediator histamine confers resistance to immunotherapy in cancer patients via activation of the macrophage histamine receptor H1. Cancer Cell 40(1):36-52.e9, 2022. e-Pub 2021. PMID: 34822775.
The Lab at AACR 2023
From left: Assistant Professor Dr. Xiangliang Yuan and graduate students Hao-Nien Chen and Shao-Ping (Emily) Yang attend AACR as poster presenters
Dr. Peter Pisters (left) and Dr. Dihua Yu
From left: Dr. Dihua Yu, Yu lab alumnus Dr. Ozgur Sahin, Dr. Xiangliang Yuan and Shao-Ping (Emily) Yang at MD Anderson Cancer Center AACR reception
Hao-Nien (left) and Dr. Yuan at Hao-Nien's poster session.
Hao-Nien presenting his poster: Engineering dendritic cell-derived exosomes forbrain metastases immunotherapy
Dr. Xiangliang Yuan (left) and Dr. Yu at Dr. Yuan's poster session
Emily and her poster: Selective-HDAC inhibitor relieves the suppressive immune microenvironment in the brain to impede breast cancer brain metastasis